William M. Greenman serves as the President and Chief Executive Officer at Cerus Corporation, a biomedical products company focused on developing and commercializing innovative technologies and products to enhance blood safety. Greenman has been instrumental in steering the company towards its mission of improving patient care by reducing the risk of transfusion-transmitted infections. Under his leadership, Cerus has seen significant growth and expanded its global presence, solidifying its position as a leader in the blood safety industry. Before joining Cerus, Greenman held various executive positions in the life sciences and medical technology sectors. He previously served as President and Chief Executive Officer of Digirad Corporation, where he successfully led the company through a period of transformation and growth. Greenman's extensive experience in the healthcare industry, coupled with his strategic vision, has been pivotal in driving Cerus' success. His leadership style emphasizes innovation, collaboration, and a strong commitment to improving patient outcomes. As CEO of Cerus, Greenman oversees the company's operations, strategic direction, and growth initiatives. He has been a driving force behind the development and commercialization of the INTERCEPT Blood System, a revolutionary technology that inactivates pathogens in blood components. Greenman's dedication to advancing blood safety has earned him recognition within the industry and among healthcare professionals worldwide. His leadership continues to guide Cerus as it works to expand its product offerings and reach new markets, ultimately aiming to enhance the safety and availability of blood transfusions globally.